Author

Q.-H. Liu

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1 Assay:imaging· 1 Organism:mouse· 1

Frequent Co-Authors

B. Qin· 1 shared H.-J. Zhu· 1 shared J. Ji· 1 shared J.-N. Wang· 1 shared J.-X. Zhao· 1 shared Q.-D. Shen· 1 shared R.-X. Sun· 1 shared S.-T. Yuan· 1 shared

Activity by Year

2023-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCell Biology

B. Qin

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Lactylation-driven FTO-mediated m6A modification of CDK2 aggravates diabetic microvascular anomalies

X. Chen, R.-X. Sun, J.-N. Wang, Y.-R. Zhang, B. Qin, Y.-C. Zhang, Y.-X. Dai, H.-J. Zhu, Y. Wang, J.-X. Zhao, W.-W. Zhang, J. Ji, S.-T. Yuan, Q.-D. Shen, Q.-H. Liu

This study shows that FTO, through lactylation-driven m6A modification of CDK2, worsens diabetic retinopathy by promoting angiogenesis and inflammation, and presents a nanotherapeutic approach to inhibit FTO.

bioRxiv · May 19, 2023 · PreprintCell Biology